Journal article
Prmt5: An emerging target for pancreatic adenocarcinoma
MKC Lee, SM Grimmond, GA McArthur, KE Sheppard
Cancers | Published : 2021
Abstract
The overall survival of pancreatic ductal adenocarcinoma (PDAC) remains poor and its incidence is rising. Targetable mutations in PDAC are rare, thus novel therapeutic approaches are needed. Protein arginine methyltransferase 5 (PRMT5) overexpression is associated with worse survival and inhibition of PRMT5 results in decreased cancer growth across multiple cancers, including PDAC. Emerging evidence also suggests that altered RNA processing is a driver in PDAC tumor-igenesis and creates a partial dependency on this process. PRMT5 inhibition induces altered splicing and this vulnerability can be exploited as a novel therapeutic approach. Three possible biological pathways underpinning the act..
View full abstractRelated Projects (1)
Grants
Awarded by Pancare Foundation
Funding Acknowledgements
This work was supported by the Peter MacCallum Cancer Centre Foundation and National Health and Medical Research Council (NHMRC) grants to G.A. McArthur and K.E. Sheppard (1158190 & 1175894); a University of Melbourne Research Scholarship by the Department of Clinical Pathology, a Royal Australiasian College of Physician Aotearoa New Zealand Fellows Research Entry Scholarship and a PanCare Foundation Onwards & Upwards Damien Woodruff Scholarship to M.K.C.L., S.M.G. is also supported by another NHMRC grant (1178568). The funders had no role in the design of the study, in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.